Press Releases and Events

PRESS RELEASES

Press Release | December 11, 2025

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | December 3, 2025

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

READ MORE
Press Release | November 20, 2025

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

READ MORE
Press Release | November 10, 2025

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | November 6, 2025

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

READ MORE
Press Release | October 23, 2025

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

READ MORE
Press Release | October 10, 2025

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | October 6, 2025

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

READ MORE
Press Release | September 25, 2025

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults

READ MORE
3 / 25